Business Description
Silverback Therapeutics Inc
NAICS : 541714
SIC : 2833
Description
Silverback Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on leveraging its ImmunoTAC technology platform to develop tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 1240.11 | |||||
| Equity-to-Asset | 0.99 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 4/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 11.3 | |||||
| 3-Year EPS without NRI Growth Rate | 10.7 | |||||
| 3-Year FCF Growth Rate | 18 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 44 | |||||
| 9-Day RSI | 51.68 | |||||
| 14-Day RSI | 54.22 | |||||
| 6-1 Month Momentum % | 73.84 | |||||
| 12-1 Month Momentum % | -40.34 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 67.87 | |||||
| Quick Ratio | 67.87 | |||||
| Cash Ratio | 66.82 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -92.9 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -28.75 | |||||
| ROA % | -27.3 | |||||
| ROIC % | -196.73 | |||||
| ROC (Joel Greenblatt) % | -1569.58 | |||||
| ROCE % | -28.81 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 0.79 | |||||
| Price-to-Tangible-Book | 0.79 | |||||
| EV-to-EBIT | 0.63 | |||||
| EV-to-EBITDA | 0.64 | |||||
| EV-to-FCF | 0.74 | |||||
| Price-to-Net-Current-Asset-Value | 0.79 | |||||
| Price-to-Net-Cash | 0.8 | |||||
| Earnings Yield (Greenblatt) % | 158.73 |
